[1] Barao I, Murphy WJ.The immunobiology of natural killer cells and bone marrow allograft rejection.Biol Blood Marrow Transplant. 2003;9(12): 727-741.[2] Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.PLoS One. 2012;7(1):e30264.[3] Hare I, Gencheva M, Evans R, et al. In Vitro Expansion of Bone Marrow Derived Mesenchymal Stem Cells Alters DNA Double Strand Break Repair of Etoposide Induced DNA Damage.Stem Cells Int. 2016;2016:8270464.[4] Capelli C, Pedrini O, Cassina G, et al. Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols.Haematologica. 2014;99(6):e94-97.[5] SchafferLG, McGowan-JordanJ, SchmidM, et al. ISCN 2013: An International System for Human Cytogenetic Nomenclature Karger, Basel.2013.[6] Heng HH, Regan SM, Liu G, et al. Why it is crucial to analyze non clonal chromosome aberrations or NCCAs. Mol Cytogenet. 2016;9:15.[7] Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells.Cell Stem Cell. 2010;7(4):521-531.[8] Barkholt L, Flory E, Jekerle V, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints.Cytotherapy. 2013;15(7): 753-759. [9] Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.Cancer Res. 2009; 69(9):4010-4017.[10] Pittari G, Filippini P, Gentilcore G, et al. Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol. 2015;6:230.[11] Lozzio CB, Lozzio BB.Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.Blood. 1975;45(3):321-334.[12] Bochtler T, Fröhling S, Krämer A.Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.Leukemia. 2015;29(6):1243-1252.[13] Bonassi S, Hagmar L, Strömberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health.Cancer Res. 2000;60(6):1619-1625.[14] Scott D, Barber JB, Spreadborough AR, et al. Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. Int J Radiat Biol. 1999;75(1):1-10.[15] Shen KC, Heng H, Wang Y, et al. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res. 2005; 65(19):8747-8753.[16] Mavrogenis AF, Patapis P, Papaparaskeva KT, et al. Extraskeletal myxoid chondrosarcoma of the perineum. Orthopedics. 2009;32(3):216.[17] Cho TJ, Kim OH, Choi IH, et al. A dominant mesomelic dysplasia associated with a 1.0-Mb microduplication of HOXD gene cluster at 2q31.1.J Med Genet. 2010;47(9):638-639.[18] Logan GE, Mor-Vaknin N, Braunschweig T, et al. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).Blood Cells Mol Dis. 2015;54(1):123-131.[19] Ohanian M, Bueso-Ramos C, Ok CY, et al. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015;208(11):571-574.[20] Prokopiou C, Koumas S, Neokleous N, et al. SET-NUP214 rearrangement in isolation is insufficient to induce leukemia: a single center experience.Leuk Lymphoma. 2015:1-2.[21] Qiu SW, Wan YL, Wang M, et al. Effects of NPM1 gene expression on acute myeloid leukemia cell lines and its mechanism.Zhonghua Xue Ye Xue Za Zhi. 2017;38(11):940-944.[22] Sharpless NE, Ferguson DO, O'Hagan RC, et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions.Mol Cell. 2001;8(6):1187-1196.[23] Kolusayin Ozar MO, Orta T.The use of chromosome aberrations in predicting breast cancer risk.J Exp Clin Cancer Res. 2005;24(2): 217-222.[24] Ye CJ, Stevens JB, Liu G, et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer.J Cell Physiol. 2009;219(2):288-300.[25] Fujisaki H, Kakuda H, Imai C, et al. Replicative potential of human natural killer cells.Br J Haematol. 2009;145(5):606-613.[26] Fang F, Xiao W, Tian Z.NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37-54.[27] 区大卫,蔡体育,李端,等. 干扰素在体外对放疗后鼻咽癌病人自然杀伤细胞功能的影响[J]. 中山医学院学报,1984,5(2):40-44.[28] 刘晓静,龚春香,范敏其,等. 放疗对食管癌患者血清可溶性MI CA含量及外周血NK细胞功能的影响[J]. 徐州医学院学报, 2009,29(8):508-511.[29] McGinnes K, Florence J, Penny R.The effect of radiotherapy on the natural killer (NK)-cell activity of cancer patients.J Clin Immunol. 1987;7(3):210-217.[30] Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.Cancer Immunol Immunother. 2007;56(5): 641-648.[31] Koda K, Saito N, Oda K, et al. Natural killer cell activity and distant metastasis in rectal cancers treated surgically with and without neoadjuvant chemoradiotherapy.J Am Coll Surg. 2003;197(2): 254-260.[32] Roos WP, Kaina B.DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis.Cancer Lett. 2013;332(2):237-248. |